What is the mechanism of action of hydroxychloroquine in treating SLE?

Hydroxychloroquine is primarily known as an antimalarial medication, but its use in treating systemic lupus erythematosus (SLE) stems from its ability to help alleviate some of the disease's symptoms, particularly skin rashes and joint pain. The mechanism of action in the context of SLE involves the drug's interference with the immune response.

While hydroxychloroquine has a range of effects, its antimalarial properties are crucial in SLE management as they help modulate the immune system. Specifically, it is thought to impede the activity of certain cells involved in the autoimmune process, decreasing inflammation and providing symptomatic relief. This action is particularly beneficial for patients suffering from cutaneous manifestations (like rashes) and arthralgia associated with SLE.

Other mechanisms, such as inhibiting cytokine production or decreasing antibody production, do play a role but they are not the primary rationale for hydroxychloroquine’s effectiveness in SLE. Rather, the antimalarial action provides specific relief from the hallmark symptoms of the disease, making it a valuable treatment option in clinical settings.